PMID: 7516410Jul 1, 1994Paper

PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: a possible cellular basis for remittive therapy

The Journal of Experimental Medicine
V P VallatJ G Krueger

Abstract

Psoriasis is characterized by alterations in both the epidermis and dermis of the skin. Epidermal keratinocytes display marked proliferative activation and differentiate along an "alternate" or "regenerative" pathway, while the dermis becomes infiltrated with leukocytes, particularly interleukin 2 (IL-2) receptor-bearing "activated" T cells. Psoralens, administered by the oral route, have therapeutic effects in psoriasis when photochemically activated by ultraviolet A light (PUVA therapy). Recently psoralen bath therapy has been introduced to more effectively deliver this agent to the diseased skin. We have correlated the efficacy of PUVA bath therapy with its effects on specific molecular and cellular parameters of disease, in 10 consecutive patients with recalcitrant psoriasis. Rapid clearing of lesions occurred in 8 out of 10 patients. Biopsies were taken from lesional and nonlesional skin before and after a single round of therapy, and observation was continued in our Clinical Research Center at The Rockefeller University. Enumeration of cycling keratinocytes with the Ki-67 monoclonal antibody showed that PUVA reduced cell proliferation by 73%. The pathological increase in insulin-like growth factor 1 (IGF-1) receptors was ...Continue Reading

References

Feb 1, 1978·The British Journal of Dermatology·J KrügerM Schlaak
Jun 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·K TurksenE Fuchs
May 1, 1991·Clinical and Experimental Dermatology·P Collins, S Rogers
Jan 31, 1991·The New England Journal of Medicine·C N EllisT G Parish
Dec 1, 1990·The Journal of Clinical Investigation·T S Kupper
Sep 1, 1988·The Journal of Experimental Medicine·A B GottliebD M Carter
Oct 1, 1988·The Journal of Experimental Medicine·G E HancockZ A Cohn
Apr 1, 1989·The British Journal of Dermatology·S LisbyG L Vejlsgaard
Aug 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·R M GrossmanA B Gottlieb
Nov 1, 1987·Journal of the American Academy of Dermatology·A K Gupta, T F Anderson
May 1, 1987·The British Journal of Dermatology·J M GommansB E van Huystee
May 1, 1986·Journal of the American Academy of Dermatology·N J LoweL S Moy

❮ Previous
Next ❯

Citations

Jan 26, 2005·Journal of Cutaneous Medicine and Surgery·Gerald G Krueger
Jul 1, 1996·Clinics in Dermatology·A C Moor, F P Gasparro
Oct 6, 2000·Journal of Controlled Release : Official Journal of the Controlled Release Society·B BaroliJ Blanco-Méndez
Jun 5, 2003·Clinics in Dermatology·Noah S ScheinfeldVincent A DeLeo
Oct 6, 1997·Clinics in Dermatology·J Lauharanta
Oct 6, 1997·Clinics in Dermatology·M A van Steensel, P M Steijlen
Mar 31, 1999·Journal of Dermatological Science·D BetheaF P Gasparro
Mar 31, 1999·Journal of Dermatological Science·K Danno
Mar 31, 1999·Journal of Dermatological Science·Y Tokura
Nov 14, 2001·Journal of Photochemistry and Photobiology. B, Biology·C AlgeB Ortel
Feb 3, 2005·Nature Reviews. Drug Discovery·Alice B Gottlieb
May 22, 2001·The British Journal of Dermatology·M Grundmann-KollmannM Podda
Dec 21, 2002·International Journal of Dermatology·Don MehrabiCalvin O McCall
Dec 10, 1999·The New England Journal of Medicine·C Robert, T S Kupper
Jul 28, 2001·The New England Journal of Medicine·C N EllisUNKNOWN Alefacept Clinical Study Group
Aug 19, 2007·The New England Journal of Medicine·Robert S Stern
Sep 30, 2005·Acta Dermato-venereologica·Florian WeberPeter Fritsch
May 1, 1996·The Australasian Journal of Dermatology·E Christophers
Jan 15, 2005·Journal of the European Academy of Dermatology and Venereology : JEADV·V SchleyerR-M Szeimies
Feb 17, 1999·Photodermatology, Photoimmunology & Photomedicine·T R CovenJ G Krueger
May 4, 1999·The Journal of Clinical Investigation·J R AbramsS Kang
Nov 5, 1999·The Journal of Clinical Investigation·J B TraversD Y Leung
Nov 24, 2007·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·L G RatkayD W Hunt
Apr 30, 2002·American Journal of Clinical Dermatology·Jennifer Cather, Alan Menter
Nov 19, 2010·Genetics and Molecular Research : GMR·C RonpirinW Chaicumpa
Dec 29, 2005·Proceedings of the National Academy of Sciences of the United States of America·Michelle A LowesJames G Krueger
Oct 23, 2002·Photodermatology, Photoimmunology & Photomedicine·Ulrike LeiterMartina Kerscher
Nov 4, 2000·Expert Opinion on Investigational Drugs·D W Hunt, A H Chan
Apr 17, 2002·Expert Opinion on Biological Therapy·Gerald G Krueger
Sep 18, 1998·The Journal of Investigative Dermatology·M LüftlK Degitz
Apr 13, 2007·The Journal of Investigative Dermatology·Johann E GudjonssonJames T Elder
Mar 12, 2002·The Journal of Investigative Dermatology·W J LinB Tomkinson
Nov 21, 2007·Clinics in Dermatology·Kamran GhoreschiMartin Röcken
May 26, 2007·The American Journal of Pathology·Laure RittiéJames T Elder

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.